The Symposium - Research papers

Sep 24, 2026 PLoS Pathogens

New Clues on COVID-19's Viral Defects

New research has found that certain defective viral genomes from the SARS-CoV-2 coronavirus can trigger different immune responses in people infected with COVID-19. These defective genomes, which are created during the virus's replication process, can either help or hinder the body's natural defense against the virus. In some cases, they even stimulate a strong immune response that can help fight off the infection. The study discovered that these defective genomes come from two specific regions of the virus and that those from one region tend to trigger stronger immune responses than those from the other. This research could lead to new treatments for COVID-19 by targeting these defective genomes.

View Source Share

Sep 14, 2026 PLoS Pathogens

Breakthrough Discovery on SARS-CoV-2 Vaccine

New research found that a specific type of nanoparticle designed to target the immune system can help neutralize different variants of the SARS-CoV-2 virus, even those that have developed resistance to existing treatments. This breakthrough could lead to more effective and long-lasting protection against COVID-19, potentially reducing the need for repeated vaccinations or boosters.

Source Share

Aug 30, 2026 PLoS Pathogens

SARS-CoV-2 Replication Linked Temperature

New research has found that the temperature of the body, particularly in the nasal cavity, plays a significant role in how well the SARS-CoV-2 virus replicates itself. The scientists discovered that the virus thrives at 37°C (body temperature) and that this is due to a specific channel called TRPV4 that allows calcium ions to flow into cells. When this channel is blocked or inhibited, the virus's ability to replicate is significantly reduced, offering new hope for developing treatments against COVID-19.

Source Share

Aug 14, 2026 JCE

COVID-19 Trials' Reliability in Question

A new study is looking at how quickly medicines for COVID-19 were tested after initial promising results, and whether that rush to approval made them more likely to be effective in the long run. During the pandemic, many treatments were moved straight from early testing to full-scale trials without much evidence of their effectiveness beforehand, or even a clear idea of how they might work. The researchers are trying to figure out if this fast-tracked approach led to medicines that actually worked as promised.

Source Share

Aug 11, 2026 PLoS Pathogens

MERS-CoV Antibody Breakthrough Neutralizes Virus

Scientists have discovered a new antibody that can effectively target the MERS-CoV virus, which causes Middle East Respiratory Syndrome. The breakthrough comes after researchers used a technique called "directed evolution" to improve the antibody's ability to bind to the virus, making it more effective at neutralizing it. This is significant because the current antibodies available for COVID-19 are not as broad in their protection, meaning they don't work against all variants of the virus. By developing this new antibody, researchers hope to create a more effective tool for fighting future pandemics and protecting people from different strains of the MERS-CoV virus.

Source Share

Aug 07, 2026 PLoS Pathogens

New Study Reveals COVID-19 Vaccine Resistance

Scientists have discovered that a specific part of the COVID-19 virus, called the S2' helix, is more resistant to antibodies designed to fight it than another similar part, the stem helix. This means that even if the virus mutates and becomes less recognizable to these antibodies, the S2' helix will be harder for them to target. Researchers tested various mutations in both parts of the virus and found that only a few minor changes in the S2' helix reduced its ability to be neutralized by antibodies, while many more significant changes occurred in the stem helix. This suggests that targeting the S2' helix could lead to the development of more effective and long-lasting COVID-19 treatments with fewer chances of the virus becoming resistant.

Source Share

Aug 07, 2026 PLoS Pathogens

Scientists Crack SARS-CoV-2 Vaccine Puzzle

Scientists have discovered a new target for COVID-19 vaccines by identifying a specific area on the virus that can trigger an immune response without neutralizing the virus. The researchers found that antibodies produced by people who have recovered from COVID-19 tend to bind to this "cryptic epitope" when the virus is in its open form, but not when it's closed. This discovery suggests that vaccines targeting this area may be more effective at preventing severe illness and death from COVID-19, even against new variants of the virus.

Source Share

Aug 07, 2026 PLoS Pathogens

New Breakthrough in SARS-CoV-2 Fight

New research has found that a specific type of molecule, called a DNA oligonucleotide, can block the entry of certain variants of the COVID-19 virus into human cells. These variants, known as Omicron, have evolved to evade the immune system and make it harder for vaccines to protect against them. The study discovered that short DNA molecules can prevent these viruses from entering cells by interfering with a specific step in their life cycle. This breakthrough offers new hope for developing treatments or prevention methods against Omicron variants, which are currently spreading rapidly around the world.

Source Share

Aug 07, 2026 PLoS Pathogens

Activating Metabolism May Boost Immunity Post-COVID

A new study has found that people who got COVID-19 are more susceptible to infections from other pathogens, such as flu and bacteria, due to a weakened immune system. Researchers discovered that the mitochondria, the energy-producing centers of cells, play a crucial role in this process. When COVID-19 infects the body, it can impair the mitochondria's function in T cells, which are a type of immune cell responsible for fighting off infections. As a result, these T cells become less effective at responding to other pathogens, making people more vulnerable to illness. The study suggests that activating mitochondrial function with certain medications may help restore the immune system's ability to fight off infections, providing new hope for those who have recovered from COVID-19 but remain susceptible to other illnesses.

Source Share

Aug 07, 2026 BMJ Medicine

UK Births Hit by Diabetes Crisis

A recent study found that nearly one in eight mothers in England now have a diagnosis of gestational diabetes, a condition that can increase the risk of complications during pregnancy. The study also revealed significant disparities in how these conditions are diagnosed and treated, with women from non-white ethnic groups and those living in deprived areas being disproportionately affected. These women were more likely to experience emergency caesarean births, preterm birth, and their babies being born small for gestational age. The COVID-19 pandemic had a limited impact on the number of diagnoses, highlighting the need for urgent action to address these health inequalities and provide better care for high-risk mothers.

Source Share

Explore Original Research

Want to dive deeper? These journals publish the original peer-reviewed research we summarize:

Nature Science The Lancet NEJM BMJ Cell JAMA PLOS ONE

Today's Top Research

Explore Original Research